文献速递免疫规划卫生政策与健康促进

改良流感疫苗研发的成就与挑战:流感疫苗研发路线图里程碑三年进展评估

Accomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap.
PubMed 文献 · Vaccine · 2025-07-01

为评估2021年发布的流感疫苗研发路线图(IVR)里程碑进展,实施了为期3年的监测、评估与调整项目。截至2025年5月中旬,93项里程碑中16项(17%)已达成或部分达成,67项(72%)处于不同进展阶段;35项高优先级里程碑中5项(14%)已达成或部分达成,29项(83%)进行中,1项(3%)无进展。

要点

  • 建立纵向队列研究以表征不同年龄和疫苗产品对流感病毒感染的免疫应答。
  • 推动下一代广谱保护性流感疫苗候选株进入临床试验。
  • 持续挑战包括明确持久广谱免疫机制、免疫印记、黏膜免疫及保护相关物。

核心结论

  • IVR监测评估项目为持续批判性审查流感疫苗研发进展提供基础,以指导研究优先事项和资金决策。

研究设计与样本

  • 2021年发布IVR后实施为期3年的监测、评估与调整(ME&A)项目,评估93项里程碑的进展。

主要发现

  • 截至2025年5月中旬,93项里程碑中16项(17%)已达成或部分达成,67项(72%)处于不同进展阶段。
  • 35项高优先级里程碑中5项(14%)已达成或部分达成,29项(83%)进行中,1项(3%)无进展。
  • 关键成就包括建立纵向队列研究、绘制创新流感疫苗技术全景、推进下一代广谱保护性疫苗进入临床试验、借鉴SARS-CoV-2疫苗加速研发经验、启动改良流感疫苗全面价值评估(FVIVA)开发。
  • 持续挑战包括阐明持久广谱免疫机制、增强对免疫印记和黏膜免疫在预防感染和传播中作用的理解、识别保护相关物、探索广谱保护性流感疫苗许可的监管选项。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Influenza vaccines that provide more effective immunity to seasonal influenza as well as protection against a broad range of emerging influenza viruses with pandemic potential are needed to reduce the public-health burden of influenza and enhance pandemic preparedness. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was published in 2021 to serve as a strategic planning tool to advance influenza vaccine R&D. Following IVR publication, a 3-year monitoring, evaluation, and adjustment (ME&A) program was implemented to assess progress in meeting the milestones outlined in the IVR. As of mid-May 2025, 16 (17%) of the 93 milestones had been accomplished or partially accomplished, with the majority (67; 72%) in various stages of progress. Of the 35 milestones designated high-priority, five (14%) had been accomplished or partially accomplished, 29 (83%) are in progress, and no progress was identified for one (3%). Key accomplishments include: establishing longitudinal cohort studies to characterize immune responses to influenza virus infection and vaccination by age over time and by vaccine product; creating a comprehensive landscape of innovative influenza vaccine technologies in preclinical and clinical development; advancing next-generation and broadly protective influenza vaccine candidates into clinical trials; identifying relevant lessons learned from accelerated SARS-CoV-2 vaccine development during the COVID-19 pandemic; and initiating development of a full value of improved influenza vaccine assessment (FVIVA) to inform investment and guide the eventual uptake of improved vaccines globally. Persistent challenges include clarifying immune mechanisms for generating durable and broadly protective immunity, enhancing understanding of immune imprinting and the role of mucosal immunity in preventing infection and transmission, identifying correlates of protection, and exploring regulatory options for broadly protective influenza vaccine licensure. The IVR ME&A program provides a basis for ongoing critical review of progress in influenza vaccine R&D to inform decision-making on research priorities and funding.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ostrowsky JT, Vestin NC, Mehr AJ, et al. Accomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap. Vaccine. 2025. PMID: 40602349. doi:10.1016/j.vaccine.2025.127431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。